Objective:
To explore the expanding role of genetic testing in retinoblastoma, particularly through liquid biopsy and molecular profiling.
Approach:
- Overview of Genetic Testing: Explores the evolution of genetic testing in retinoblastoma, highlighting its transition from solely detecting germline mutations to encompassing diagnostic and prognostic applications.
Key Findings:
- Aqueous humor liquid biopsy demonstrated a feasibility rate of 98% with a sensitivity of 98% and specificity of 100% for detecting active disease.
- Circulating tumor DNA can be detected in up to 85% of untreated unilateral retinoblastoma patients, reflecting tumor burden.
- Chromosome 6p gain, 7q gain, and MYCN amplification are associated with poorer globe salvage outcomes.
- Blood ctDNA levels correlate with ocular disease progression and regression following intra-arterial chemotherapy.
Interpretation:
Genetic testing in retinoblastoma is evolving to include liquid biopsy and molecular profiling, enhancing diagnostic sensitivity and prognostic capabilities.
Limitations:
- False-negative results may occur in small tumors or those with low tumor DNA shedding.
- The number of reported patients in studies is small, and further validation is needed.
Conclusion:
Emerging genetic testing strategies in retinoblastoma may lead to improved individualized management and surveillance.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.